disease interaction(s) of multiple sclerosis with obesity
Jump to navigation
Jump to search
Management
- treatment of obesity or type-2 diabetes lowers risk of MS[1]
- semaglutide lowers risk of MS by 76%
- dulaglutide lowers risk of MS by 84%
- liraglutide lowers risk of MS by 84%
- empagliflozin lowers risk of MS by 77%[1]
More general terms
References
- ↑ 1.0 1.1 1.2 Shirani A, Cross AH, Stuve O Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database. Ther Adv Neurol Disord. 2024 Apr 1;17:17562864241241383 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38566910 PMCID: PMC10986166 Free PMC article https://journals.sagepub.com/doi/10.1177/17562864241241383